BOOKS BY CATEGORY
Your Account
Biomarkers in Breast Cancer
Price
Quantity
£193.00
(To see other currencies, click on price)
Paperback / softback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.


Back cover:

It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.

Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy.


Contents:

Part I. General Topics

Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically Relevant Biomarkers and Biomarker-Based Classification Systems
Richard M. Simon

Analytical Aspects of Biomarker Immunoassays in Cancer Research
Fred C. G. J. Sweep, Chris M. G. Thomas, and Manfred Schmitt

Tissue Microarrays: State of the Art, Pitfalls, and Promises
Chungyeul Kim and Soonmyung Paik

Part II. Assays for Gene Expression and Post-Translational Protein Abnormalities

Gene Expression Profiling with DNA Microarrays: Revolutionary Tools to Help Diagnosis, Prognosis, Treatment Guidance, and Drug Discovery
Michele De Bortoli and Nicoletta Biglia

Part III. Assays for DNA Abnormalities

Assays for Gene Amplification: State of the Art, Pitfalls, and Promises
Chungyeul Kim, Yongkuk Song, and Soonmyung Paik

Part IV. Tissue Predictive Biomarkers

Cell Kinetics
Maria Grazia Daidone, Rosella Silvestrini, and Dino Amadori

Urokinase-Type Plasminogen Activator and PAI-1: Validated Prognostic Factors for Breast Cancer
Michael J. Duffy

Predictive Value of c-erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer
Vered Stearns

erb-B2 as a Therapeutic Target
Robert Mass

The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer
Fortunato Ciardiello, Teresa Troiani, and Giampaolo Tortora

p53 as a Prognostic and Predictive Indicator
Daniela Kandioler and Raimund Jakesz

Part V. Predictive Biomarkers in Body Fluids

Occult Metastatic Cells in Breast Cancer Patients: State of the Art, Pitfalls, and Promises
Stephan Braun, Julia Seeber, and Christian Marth

Circulating HER2/neu: Clinical Utility
Allan Lipton, Laurence Demers, Kim Leitzel, Suhail M. Ali, Rainer Neumann, Christopher P. Price, and Walter P. Carney

Circulating Vascular Endothelial Growth Factor: Methods, Prognostic Significance, and Potential Application for Antiangiogenic Therapy
Roberta Sarmiento, Roberta Franceschini, Sabrina Meo, Massimo Gion, Raffele Longo, and Giampietro Gasparini

Detection of Early Tumor Dissemination in Patients with Breast Cancer
Debra Hawes and Richard J. Cote

Part VI. Future Directions

New Technologies/New Markers/New Challenges
Daniel F. Hayes and Giampietro Gasparini

Index


PRODUCT DETAILS

ISBN-13: 9781617374364
Publisher: Springer (Humana Press)
Publication date: December, 2010
Pages: 354
Weight: 517g
Availability: POD
Subcategories: Oncology
Related books
From the same series

CUSTOMER REVIEWS

Average Rating